Conversion calendar in hand: management narrates the coming year as dated deliveries of business already secured
The model's full reasoning — Q4 2021 call → NOWe need to determine if management lays out a timetable of specific conversions that are already secured or in motion, with timing, and presents that as the forward story. Let's examine the transcript. Key points from management's remarks: - They discuss AMP-100 with a PDUFA date of October 16 (this year). But that's an approval date, not yet approved. They say "if approved" and "we intend to be ready a few months thereafter to launch." So it's contingent on FDA approval, which is not yet secured. So that doesn't count as already real. - They mention expanding commercial infrastructure, adding sales executives, etc. That's preparation, not secured business. - They mention Surface Opthalmics and Melt Pharmaceuticals reporting data on studies. Those are events, not conversions of secured business. They are noncontrolling equity positions, not core business. - They talk about relaunching IOPIDINE, MAXITROL, MOXEZA under their umbrella. But are these already secured? They have the products? They mention "relaunch" but no specific timing or that they are already in motion with committed customers. It's vague. - They mention "internally developed formulations that we expect to launch commercially over the next 18 months or so." That's vague and not specific. - They mention "we continue to be on the hunt for additional M&A opportunities" - that's not secured. - They mention "we are expanding our existing commercial infrastructure" - that's not a conversion of business. - They mention "we are also in the process of establishing our own internal analytical lab" - that's operational, not revenue-generating. - They mention "we continue to see strong daily revenues to this day" - that's current performance, not future scheduled conversions. - They mention "we expect to see value creation events from our noncontrolling equity positions" - but those are not core business conversions. - They mention "we expect Surface Opthalmics to report data on a major chronic dry eye study" - that's a data readout, not a secured business conversion. - They mention "we expect Melt Pharmaceuticals to report top line data" - same. - They mention "we will continue to grow our core ophthalmic pharmaceuticals business, launch new ophthalmic products we've been internally developing and review the potential for new accretive transactions" - that's general.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
CPK · Q3 2017 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured business and approximate time frames.
SOL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.
FLL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.